Insmed | INSM - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Cytokinetics USD 129.84M 7.32M 2026-03
DBV Technologies USD 194.17M 124.33M 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
Heron Therapeutics USD 26.12M 2.53M 2026-03
Insmed USD 582.19M 71.74M 2026-03
Novartis USD 9.56B 2.9B 2025-09
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03